Translating NCCN Guidelines speaks directly to the NCCN mission of making NCCN Content accessible to providers and patients globally. As a result, NCCN works to translate the NCCN Guidelines into multiple languages and publishes these important resources on NCCN.org as well as within NCCN mobile application for free so that they may be accessed by clinicians around the world.
Acute Lymphoblastic Leukemia Version 1.2022 (Chinese)
Acute Myeloid Leukemia Version 2.2022 (Chinese)
B-Cell Lymphomas Version 5.2022 (Chinese)
Bladder Cancer Version 2.2022 (Chinese)
Breast Cancer Version 4.2022 (Chinese)
Cervical Cancer Version 1.2022 (Chinese)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 3.2022 (Chinese)
Chronic Myeloid Leukemia Version 2.2020 (Chinese)
Colon Cancer Version 1.2022 (Chinese)
Esophageal and Esophagogastric Junction Cancers Version 3.2022 (Chinese)
Gastric Cancer Version 2.2022 (Chinese)
Gestational Trophoblastic Neoplasia Version 1.2022 (Chinese)
Hairy Cell Leukemia Version 1.2021 (Chinese)
Head and Neck Cancers Version 2.2022 (Chinese)
Hepatobiliary Cancers Version 4.2022 (Chinese)
Hodgkin Lymphoma Version 4.2021 (Chinese)
Melanoma: Cutaneous Version 3.2022 (Chinese)
Multiple Myeloma Version 5.2022 (Chinese)
Myelodysplastic Syndromes Version 1.2023 (Chinese)
Non-Small Cell Lung Cancer Version 3.2022 (Chinese)
Pediatric Acute Lymphoblastic Leukemia Version 2.2023 (Chinese)
Primary Cutaneous Lymphomas Version 2.2022 (Chinese)
Prostate Cancer Version 4.2022 (Chinese)
Small Cell Lung Cancer Version 1.2023 (Chinese)
Soft Tissue Sarcoma Version 2.2020 (Chinese)
T-Cell Lymphomas Version 1.2021 (Chinese)
Uterine Neoplasms Version 1.2022 (Chinese)
Vulvar Cancer Version 1.2022 (Chinese)
Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma Version 1.2023 (Chinese)
Acute Lymphoblastic Leukemia Version 1.2022 (French)
B-Cell Lymphomas Version 4.2020 (French)
Breast Cancer Version 8.2021 (French)
Colon Cancer Version 3.2021 (French)
Hairy Cell Leukemia Version 2.2018 (French)
Hodgkin Lymphoma Version 3.2018 (French)
Multiple Myeloma Version 5.2022 (French)
Non-Small Cell Lung Cancer Version 3.2022 (French)
Pediatric Acute Lymphoblastic Leukemia Version 2.2023 (French)
T-Cell Lymphomas Version 2.2022 (French)
Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma Version 1.2023 (French)
B-Cell Lymphomas Version 4.2020 (German)
Multiple Myeloma Version 5.2022 (German)
T-Cell Lymphomas Version 2.2022 (German)
Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma Version 1.2023 (German)
Acute Lymphoblastic Leukemia Version 4.2021 (Italian)
B-Cell Lymphomas Version 4.2020 (Italian)
Breast Cancer Version 2.2022 (Italian)
Hairy Cell Leukemia Version 1.2021 (Italian)
Hodgkin Lymphoma Version 4.2021 (Italian)
Multiple Myeloma Version 5.2022 (Italian)
Non-Small Cell Lung Cancer Version 8.2020 (Italian)
Pediatric Acute Lymphoblastic Leukemia Version 1.2022 (Italian)
Primary Cutaneous Lymphomas Version 2.2022 (Italian)
T-Cell Lymphomas Version 1.2020 (Italian)
Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma Version 1.2023 (Italian)
Acute Lymphoblastic Leukemia Version 1.2022 (Japanese)
Bladder Cancer Version 4.2019 (Japanese)
Breast Cancer Version 5.2020 (Japanese)
Breast Cancer Risk Reduction Version 1.2019 (Japanese)
Breast Cancer Screening and Diagnosis Version 1.2019 (Japanese)
Cervical Cancer Version 4.2019 (Japanese)
Gestational Trophoblastic Neoplasia Version 2.2019 (Japanese)
Hematopoietic Growth Factors Version 2.2019 (Japanese)
Kidney Cancer Version 1.2021 (Japanese)
Lung Cancer Screening Version 2.2018 (Japanese)
Management of Immunotherapy-Related Toxicities Version 2.2019 (Japanese)
Mesothelioma: Pleural Version 2.2019 (Japanese)
Multiple Myeloma Version 5.2022 (Japanese)
Non-Small Cell Lung Cancer Version 2.2018 (Japanese)
Occult Primary Version 2.2019 (Japanese)
Pancreatic Adenocarcinoma Version 2.2021 (Japanese)
Pediatric Acute Lymphoblastic Leukemia Version 2.2023 (Japanese)
Penile Cancer Version 2.2019 (Japanese)
Prostate Cancer Version 4.2019 (Japanese)
Prostate Cancer Early Detection Version 2.2019 (Japanese)
Small Cell Lung Cancer Version 2.2018 (Japanese)
Smoking Cessation Version 2.2019 (Japanese)
Thymomas and Thymic Carcinomas Version 2.2019 (Japanese)
Uterine Neoplasms Version 1.2018 (Japanese)
Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma Version 1.2023 (Japanese)
Breast Cancer Version 6.2020 (Korean)
Colon Cancer Version 1.2022 (Korean)
Hodgkin Lymphoma Version 3.2018 (Korean)
Multiple Myeloma Version 5.2022 (Korean)
Non-Small Cell Lung Cancer Version 3.2022 (Korean)
Breast Cancer Version 6.2020 (Polish)
Colon Cancer Version 3.2021 (Polish)
Multiple Myeloma Version 1.2023 (Polish)
Non-Small Cell Lung Cancer Version 1.2021 (Polish)
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 5.2022 (Polish)
Acute Myeloid Leukemia Version 2.2022 (Portuguese - Latin America Editions)
B-Cell Lymphomas Version 4.2022 (Portuguese)
Breast Cancer Version 6.2020 (Portuguese)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 3.2022 (Portuguese)
Colon Cancer Version 3.2021 (Portuguese)
Hairy Cell Leukemia Version 2.2018 (Portuguese)
Head and Neck Cancers Version 3.2021 (Portuguese)
Hodgkin Lymphoma Version 3.2018 (Portuguese)
Multiple Myeloma Version 5.2022 (Portuguese - Latin America Editions)
Myelodysplastic Syndromes Version 1.2023 (Portuguese)
Non-Small Cell Lung Cancer Version 7.2021 (Portuguese)
Pediatric Acute Lymphoblastic Leukemia Version 2.2023 (Portuguese)
Prostate Cancer Version 2.2021 (Portuguese)
T-Cell Lymphomas Version 2.2022 (Portuguese)
Colon Cancer Version 1.2022 (Romanian)
Multiple Myeloma Version 1.2023 (Romanian)
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 5.2022 (Romanian)
Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma Version 1.2023 (Romanian)
Management of Immunotherapy-Related Toxicities Version 1.2020 (Russian)
Multiple Myeloma Version 1.2023 (Russian)
Pediatric Acute Lymphoblastic Leukemia Version 1.2021 (Russian)
Acute Lymphoblastic Leukemia Version 1.2022 (Spanish)
Acute Myeloid Leukemia Version 2.2022 (Spanish - Latin America Editions)
B-Cell Lymphomas Version 4.2020 (Spanish)
Breast Cancer Version 2.2022 (Spanish)
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 3.2022 (Spanish)
Chronic Myeloid Leukemia Version 2.2020 (Spanish)
Colon Cancer Version 3.2021 (Spanish)
Gastric Cancer Version 3.2020 (Spanish)
Hairy Cell Leukemia Version 1.2021 (Spanish)
Head and Neck Cancers Version 2.2022 (Spanish)
Hodgkin Lymphoma Version 1.2023 (Spanish)
Melanoma: Cutaneous Version 3.2022 (Spanish)
Multiple Myeloma Version 5.2022 (Spanish - European Editions)
Multiple Myeloma Version 5.2022 (Spanish - Latin America Editions)
Myelodysplastic Syndromes Version 3.2022 (Spanish - Latin America Editions)
Non-Small Cell Lung Cancer Version 3.2022 (Spanish)
Pediatric Acute Lymphoblastic Leukemia Version 2.2023 (Spanish)
Primary Cutaneous Lymphomas Version 2.2021 (Spanish)
Prostate Cancer Version 2.2021 (Spanish)
T-Cell Lymphomas Version 1.2021 (Spanish)
Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma Version 1.2023 (Spanish)
Breast Cancer Version 2.2022 (Ukrainian)
Colon Cancer Version 1.2022 (Ukrainian)
Multiple Myeloma Version 1.2023 (Ukrainian)
Myelodysplastic Syndromes Version 1.2023 (Ukrainian)
Non-Small Cell Lung Cancer Version 3.2022 (Ukrainian)
Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer Version 5.2022 (Ukrainian)
Pediatric Acute Lymphoblastic Leukemia Version 2.2023 (Ukrainian)
Waldenström Macroglobulinemia / Lymphoplasmacytic Lymphoma Version 1.2023 (Ukrainian)
NCCN MAKES NO REPRESENTATIONS OR WARRANTIES CONCERNING THE NCCN CONTENT, THE NCCN GUIDELINES OR DERIVATIVE RESOURCES PROVIDED BY NCCN, ALL OF WHICH ARE PROVIDED "AS IS." NCCN DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. NCCN DOES NOT WARRANT THE ACCURACY, APPROPRIATENESS, APPLICABILITY OR COMPLETENESS OF THE NCCN CONTENT, THE NCCN GUIDELINES OR ANY DERIVATIVE RESOURCES, NOR DOES NCCN MAKE ANY REPRESENTATIONS REGARDING THE USE OR RESULTS OF THE USE OF THE NCCN CONTENT, THE NCCN GUIDELINES OR ANY SUCH DERIVATIVE RESOURCES.
NCCN EXPLICITLY DISCLAIMS THE APPROPRIATENESS OR APPLICABILITY OF THE NCCN CONTENT, THE NCCN GUIDELINES, AND ANY DERIVATIVE RESOURCES, OR THE USE OR APPLICATION OF THE NCCN CONTENT, THE NCCN GUIDELINES OR ANY SUCH DERIVATIVE RESOURCES, TO ANY SPECIFIC PATIENT'S CARE OR TREATMENT. ANY CLINICIAN SEEKING TO APPLY OR CONSULT THE NCCN CONTENT, THE NCCN GUIDELINES AND/OR ANY DERIVATIVE RESOURCES IS EXPECTED TO USE INDEPENDENT MEDICAL JUDGMENT IN THE CONTEXT OF THE INDIVIDUAL CLINICAL CIRCUMSTANCES TO DETERMINE ANY PATIENT'S CARE OR TREATMENT.